UBS Initiates Coverage On Mineralys Therapeutics with Neutral Rating, Announces Price Target of $29

Benzinga Newsdesk www.benzinga.com Neutral 81.3%

Neg 0% Neu 81.3% Pos 0%

UBS analyst Alice Nettleton initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Neutral rating and announces Price Target of $29.